Switching from twice-daily abacavir and lamivudine to the once-daily fixed-dose combination tablet of abacavir and lamivudine improves patient adherence and satisfaction with therapy
- 1 September 2008
- journal article
- research article
- Published by Wiley in HIV Medicine
- Vol. 9 (8), 667-672
- https://doi.org/10.1111/j.1468-1293.2008.00618.x
Abstract
Patients prefer fewer pills and once-daily (qd) dosing without food restrictions. We assessed the impact on adherence [by Medication Event Monitoring System (MEMS) cap monitoring] of switching from abacavir (ABC) and lamivudine (3TC) twice daily (bid) to ABC/3TC fixed-dose formulation (FDC, Kivexa) qd to achieve a qd regimen. A randomized, open-label, 8-week study comparing adherence, efficacy and safety of immediate vs. delayed switching from ABC/3TC to FDC qd. Ninety-four patients were dosed. Significantly improved adherence was observed at week 4 with qd ABC/3TC across all three adherence variables: taking compliance 99.2% (90.7-100%) vs. 96.6% (60.0-100%) (P=0.017); dosing compliance 97.1% (64.3-100%) vs. 91.9% (33.3-100%) (P=0.016); and timing compliance 95.5% (53.8-100%) vs. 86.3% (4.3-100%) (P=0.006). Treatment satisfaction increased significantly at week 4 with ABC/3TC qd [92% (82-99%) vs. 85% (75-93%) (P=0.004)]. Two patients were withdrawn from the study because of intolerance to ABC/3TC. Switching from ABC and 3TC bid to ABC/3TC FDC qd significantly improved adherence by MEMS cap monitoring at week 4 and improved patient satisfaction with therapy. The results remain to be confirmed over a longer follow-up. Use of qd regimens supports adherence and improves treatment satisfaction relative to bid regimens.Keywords
This publication has 16 references indexed in Scilit:
- Discordant Immunologic and Virologic Responses to Highly Active Antiretroviral Therapy Are Associated With Increased Mortality and Poor Adherence to TherapyJAIDS Journal of Acquired Immune Deficiency Syndromes, 2005
- Better maintained adherence on switching from twice‐daily to once‐daily therapy for HIV: a 24‐week randomized trial of treatment simplification using stavudine prolonged‐release capsulesHIV Medicine, 2005
- Abacavir Once or Twice Daily Combined With Once-Daily Lamivudine and Efavirenz for the Treatment of Antiretroviral-Naive HIV-Infected AdultsJAIDS Journal of Acquired Immune Deficiency Syndromes, 2005
- Perspectives on Adherence and Simplicity for HIV-Infected Patients on Antiretroviral TherapyJAIDS Journal of Acquired Immune Deficiency Syndromes, 2004
- The Assessing Patients' Preferred Treatments (APPT-1) studyInternational Journal of STD & AIDS, 2003
- Knowledge of Antiretroviral Regimen Dosing and Adherence: A Longitudinal StudyClinical Infectious Diseases, 2003
- Association between presence of HLA-B*5701, HLA-DR7 , and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavirThe Lancet, 2002
- A systematic review of the associations between dose regimens and medication complianceClinical Therapeutics, 2001
- Highly Active Antiretroviral Therapy Decreases Mortality and Morbidity in Patients with Advanced HIV DiseaseAnnals of Internal Medicine, 2001
- Sociodemographic and psychological variables influencing adherence to antiretroviral therapyAIDS, 1999